Most Read Articles
Elvira Manzano, 16 Jan 2019
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
Pearl Toh, 12 Jan 2019
Two novel investigational topical agents show potential in improving symptoms of atopic dermatitis, according to early phase trials presented at the Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria.
25 Jan 2019
Daylight photodynamic therapy (DLPDT) represents a promising treatment option for actinic keratoses, with the results of a meta-analysis showing that while comparable to conventional PDT in terms of efficacy, DLPDT is associated with less pain and high patient satisfaction.
27 Jan 2019
A treatment regimen containing oral tetracycline and nicotinamide plus topical clobetasol appears to be effective in the treatment of bullous pemphigoid, yielding better survival rates compared with prednisone, according to a study.

Anti-TNF agents may contribute to increased risk of psoriasiform diseases in IBD

04 Jul 2018

Use of antitumour necrosis factor (anti-TNF) agents in patients with inflammatory bowel disease (IBD) appears to be associated with an increased likelihood of developing psoriasiform diseases, with the risk of palmoplantar pustulosis most pronounced in males and younger patients, according to a study.

Drawing data from the Korea National Health Insurance Claim Data, researchers looked at 5,428 IBD patients treated with any anti‐TNF agent for >6 months (anti‐TNF group) and 10,856 matched controls who had never taken anti‐TNF agents (control group).

Psoriasis occurred with significantly greater frequency in the anti‐TNF vs control group (36.8 vs 14.5 per 10,000 person‐years). Use of anti-TNF was associated with a more than twofold increase in the risk of developing psoriasis (hazard ratio [HR], 2.357; 95 percent CI, 1.668–3.331).

Moreover, the anti-TNF group had greater risks of palmoplantar pustulosis (HR, 9.355; 2.754–31.780) and psoriatic arthritis (HR, 2.926; 1.640–5.218).

When analyses were stratified according to IBD subtypes, anti-TNF agent use was associated with a heightened risk of psoriasis in both Crohn’s disease (HR, 2.549; 1.658–3.920) and ulcerative colitis (HR, 2.105; 1.155–3.836).

Of note, the risk of palmoplantar pustulosis was markedly higher in subgroups of male (HR, 19.682; 3.867–100.169) and younger (aged 10–39 years; HR, 14.318; 2.915–70.315) patients exposed to anti-TNF agents.

The present data underscore the need for evaluating paradoxical psoriasiform diseases carefully when prescribing or considering anti‐TNF agents for IBD patients, as researchers pointed out. More studies are warranted to characterize the predictive factors for this phenomenon.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 16 Jan 2019
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
Pearl Toh, 12 Jan 2019
Two novel investigational topical agents show potential in improving symptoms of atopic dermatitis, according to early phase trials presented at the Inflammatory Skin Disease Summit (ISDS) in Vienna, Austria.
25 Jan 2019
Daylight photodynamic therapy (DLPDT) represents a promising treatment option for actinic keratoses, with the results of a meta-analysis showing that while comparable to conventional PDT in terms of efficacy, DLPDT is associated with less pain and high patient satisfaction.
27 Jan 2019
A treatment regimen containing oral tetracycline and nicotinamide plus topical clobetasol appears to be effective in the treatment of bullous pemphigoid, yielding better survival rates compared with prednisone, according to a study.